###begin article-title 0
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Role of MYOC and OPTN sequence variations in Spanish patients with Primary Open-Angle Glaucoma
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 51 59 51 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 71 81 71 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">optineurin</italic>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
To retrospectively investigate the contribution of myocilin (MYOC) and optineurin (OPTN) sequence variations to adult-onset ocular hypertension (OHT) and primary open-angle glaucoma (POAG) in Spanish patients.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 261 265 261 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
The promoter region and the three exons of MYOC were analyzed by direct PCR DNA sequencing in 40 OHT and 110 POAG unrelated patients. We used 98 subjects in whom OHT or glaucoma had been ruled out as controls. We also screened the complete coding region of the OPTN gene (exons 4-16) in all subjects by single-stranded conformational polymorphisms (SSCPs).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 90 94 90 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 642 646 642 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
We identified six common single nucleotide polymorphisms (SNPs) in the promoter region of MYOC (-1000C>G, -387C>T, -306G>A, -224T>C, -126T>C and -83G>A) and a polymorphic GT microsatellite (-339(GT)11-19). In addition, we detected four novel, rare DNA polymorphisms. None of these DNA sequence variations were associated with either OHT or POAG. We also found three (2.7%) POAG patients with MYOC pathogenic mutations. Two of these pathogenic mutations (Gln368Stop and Ala445Val) were previously described whereas the third (Tyr479His) was novel. Transient expression of the novel mutation in 293T cells supported its pathogenicity. Only two OPTN polymorphisms, which are not associated with the disease, were detected.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 162 166 162 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Overall, our data show that in Spain a minority of adult-onset high-pressure POAG patients carry heterozygous disease-causing mutations in the MYOC gene and that OPTN is not involved in either OHT or POAG.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 252 253 252 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 254 255 254 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 848 849 848 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 1197 1198 1197 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 1430 1431 1430 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 610 616 <span type="species:ncbi:9606">people</span>
Glaucoma is a complex and genetically heterogeneous disease characterized by the progressive apoptotic death of retinal ganglion cells. This process leads to the excavation of the optic nerve head and to progressive and irreversible visual field loss [1,2]. Glaucoma is the second leading cause of blindness with prevalence of 0.15% in the total population and of approximately 2-4% among the population over the age of 40. Primary open-angle glaucoma (POAG) is the most common form of glaucoma, that manifests as an insidious and chronic condition characterized by a gonioscopically open angle. Although most people will not develop glaucomatous damage despite having an intraocular pressure (IOP) well above 21 mmHg, elevated IOP (>21 mmHg), originated by an increase in aqueous outflow resistance, is the most important risk factor in glaucoma [3]. It is speculated that elevated IOP could compress the optic nerve at the lamina cribosa. Depending on individual susceptibility factors, elevated IOP might damage ganglion cell axons and local glial cells as well as impair the capillary blood supply to the region. These events could progressively lead to the apoptotic death of ganglion cells [4]. Other risk factors include age, gender, myopia, and vascular and genetic factors. It has also been reported that changes in expression of genes such as p21(WAF1/CIP1) and 14-3-3 sigma may indicate an increased risk for glaucoma [5].
###end p 10
###begin p 11
###xml 108 116 108 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 561 567 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 284 289 <span type="species:ncbi:9606">human</span>
Genetically, POAG shows a complex pattern of inheritance with sporadic manifestations in most patients. The myocilin (MYOC) gene is mutated in 3-5% of sporadic patients in populations around the world [6-10]. This gene is composed of three exons and is ubiquitously expressed in many human tissues including the iris, ciliary body, and trabecular meshwork (TM) [11-13]. The majority of MYOC disease-causing mutations map to the olfactomedin-like domain of the protein, which is encoded by exon 3 [12]. In addition, heterozygous mutations in cytochrome P450 1B1 CYP1B1, a gene involved in primary congenital glaucoma, have been identified in 4-9% of affected POAG subjects from France [14,15], India [16], and Spain [17].
###end p 11
###begin p 12
###xml 4 14 4 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">optineurin</italic>
###xml 16 20 16 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 92 96 92 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 190 192 190 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
The optineurin (OPTN) gene consists of sixteen exons and the first three are noncoding. The OPTN gene is expressed in ocular tissues such as retina, TM, and nonpigmented ciliary epithelium [18]. Mutations in this gene predominately result in normal tension glaucoma [18], a subtype of glaucoma featured by normal IOP, but its role in high-pressure POAG is still controversial.
###end p 12
###begin p 13
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 121 125 121 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 301 305 301 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 397 401 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 460 468 <span type="species:ncbi:9606">patients</span>
We report the first complete mutational analysis of the promoter and coding regions of MYOC and the coding region of the OPTN gene in Spanish patients diagnosed with adult-onset POAG. We found in this population, disease-causing mutations in the olfactomedin-like domain, encoded by the third exon of MYOC, are present in 2.7% of sporadic POAG cases. Our data also enable us to rule out a role of OPTN sequence variations in the development of POAG in Spanish patients.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Subjects
###end title 15
###begin p 16
###xml 137 141 137 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
One hundred and ten unrelated native Spanish patients diagnosed with POAG and forty diagnosed with OHT, were studied retrospectively for MYOC and OPTN mutations. The control group was composed of 98 individuals in whom glaucoma was ruled out. All the individuals were recruited in the Department of Ophthalmology, University Hospital of Albacete, Spain ("Servicio de Oftalmologia, Complejo Hospitalario Universitario de Albacete").
###end p 16
###begin p 17
###xml 629 634 <span type="species:ncbi:9606">Human</span>
The following conditions were required to diagnose POAG: exclusion of secondary causes (e.g., trauma, uveitis, steroid-induced or neovascular glaucoma); open anterior chamber angle (grade III-IV gonioscopy); IOP higher than 21 mmHg; characteristic optic disc changes; and an alteration of the visual field, tested by automated perimetry (with Humphrey's perimeter). The global indices such as mean deviation (MD) and pattern standard deviation (PSD) of the baseline visual fields were analyzed for all cases. All study subjects underwent a complete ocular examination. The study protocol was approved by the Ethics Committee for Human Research of the University Hospital of Albacete and followed the tenets of the Declaration of Helsinki. Informed consents were obtained from all the study subjects.
###end p 17
###begin p 18
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients were classified as having early (MD better than -6 dB), moderate (MD between -6 and -12 dB), or severe (MD worse than -12 dB) visual field alteration according to the classification by Hodapp et al. [19]. Medical treatment primarily included topical beta-blockers and prostaglandin analogues.
###end p 18
###begin title 19
Sequence variation screening
###end title 19
###begin p 20
###xml 249 253 249 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 343 350 343 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 478 479 477 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 510 511 509 510 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 758 765 750 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
Genomic DNA was extracted from the peripheral leukocytes of all studied subjects with the Perfect gDNA Blood Mini kit (Eppendorf, Madrid, Spain) according to the manufacturer's protocol. The promoter (nucleotides -1 to -1117) and the three exons of MYOC were amplified using primers designed to allow analysis of splicing consensus sequences (Table 1). PCRs were performed in a 50 mul volume containing 50-100 ng of genomic DNA, 10 pmol of forward and reverse primers, 2 mM MgCl2 for exons 1 and 3, 0.5 mM MgCl2 for exon 2, 100 muM of each dNTP, and 1 U of Taq DNA polymerase (Biotools, B&M Labs, Madrid, Spain). Thermocycling included an initial denaturation step at 94 degreesC for four min followed by 35 cycles of denaturation, annealing, and extension (Table 1). A final cycle was performed at 72 degreesC for seven min. Terminator cycle sequencing was carried out using the BigDye(R) (v3.1) kit (Applied Biosystems, Foster City, CA). The products of sequencing reactions were analysed in an automated capillary DNA sequencer (ABI Prism 3100-Avant genetic analyzer; Applied Biosystems).
###end p 20
###begin title 21
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
Oligonucleotide primers used for amplification of the myocilin gene.
###end title 21
###begin p 22
Annealing temperature and time, extension time for each primer pair and the predicted length for each of the PCR DNA products in base pairs (bp) are listed. In the Primer sequence column, F indicates forward and R indicates reverse.
###end p 22
###begin title 23
Single stranded conformational polymorphism analysis
###end title 23
###begin p 24
###xml 47 51 47 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 207 214 206 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 329 330 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 572 579 564 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 1095 1102 1073 1080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 1145 1147 1123 1125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 1376 1378 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
Mutations in the 13 coding exons (4-16) of the OPTN gene were screened by PCR-SSCP. Each exon was amplified by PCR in 50 mul reaction volumes using the primers, annealing temperatures, and times detailed in Table 2. Primers were also designed to allow analysis of splicing consensus sequences. Each reaction contained 2.0 mM MgCl2, 10 pmol of forward and reverse primers, 100-200 muM dNTPs, 0.5 U Taq Polymerase (Biotools), and 50-100 ng of genomic DNA. Reactions were denatured at 94 degreesC for four min followed by 35 cycles of denaturation, annealing, and extension (Table 2) as well as a final extension of 72 degreesC for seven min. PCR products (2-4 mul) were added to two volumes (4-8 mul) of SSCP stop solution consisting of 95% deionized formamide, 10 mM EDTA, 1 mg/ml Bromophenol blue, 1 mg/ml Xylene Cyanol (all these reagents were supplied by Sigma-Aldrich, St. Louis, MO), were denatured at 95 degreesC for ten min, and were chilled on ice for five min. The presence of abnormally migrating bands was confirmed by three different electrophoretic conditions using acrylamide gels (Table 3). Electrophoresis was performed on a DCodeTM Universal Mutation Detection System (Bio-Rad, Hercules, CA) in 0.5X TBE buffer (45 mM Tris, 45 mM boric acid, 1 mM EDTA). After the run, gels were removed from the apparatus and the DNA bands were visualized by silver staining [20]. Mobility shift of single-strand DNA from the normal pattern indicated the presence of a possible mutation and was further investigated by sequence analysis of genomic DNA.
###end p 24
###begin title 25
###xml 54 64 54 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">optineurin</italic>
Oligonucleotide primers used for amplification of the optineurin gene.
###end title 25
###begin p 26
Annealing temperature and time, extension time for each primer pair and the predicted length for each of the PCR DNA products in base pairs (bp) are listed. In the Primer sequence column, F indicates forward and R indicates reverse.
###end p 26
###begin title 27
Electrophoretic conditions used for single-stranded conformational polymorphism analysis.
###end title 27
###begin p 28
Acrylamide/bisacrylamide and glycerol composition of the gels as well as temperature and voltage used for electrophoresis are indicated.
###end p 28
###begin title 29
Linkage disequilibrium and haplotype construction
###end title 29
###begin p 30
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
Pairwise linkage disequilibrium (LD) between the SNPs with minor allele frequencies (MAF) higher than 5% was measured as D' [21] using the  software version 3.2 [22]. Regions of strong LD (LD blocks) were inferred using the confidence-interval model proposed by Gabriel and colleagues [23] as implemented in Haploview. Haplotype reconstruction was done with the expectation-maximization algorithm in  v. 3.22 [24].
###end p 30
###begin title 31
Statistical analysis
###end title 31
###begin p 32
###xml 132 133 132 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
The significance of the difference in frequencies of DNA polymorphisms between patients and control subjects was determined by the x2 test when all expected values were five or more. The Fisher's exact test was used when expected values were less than five. Data were statistically treated by using the SigmaStat 2.0 software (SPSS Science, Inc., Chicago, IL).
###end p 32
###begin title 33
Expression of mutant myocilin in 293T cells
###end title 33
###begin p 34
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
Myocilin point mutations were obtained as previously described [25]. The specific PCR primers used for mutagenesis were: 5'-CCA GAA CTG TCA TAA CAT ATG AGC TGA ATA CC-3' (forward) and 5'-GGT ATT CAG CTC ATA TGT TAT GAC AGT TCT GG-3' (reverse) for Arg346Thr; 5'-CAG CAG CAT GAT TGA CCA CAA CCC CCT GGA GAA G-3' (forward) and 5'-CTT CTC CAG GGG GTT GTG GTC AAT CAT GCT GCT G-3' (reverse) for Tyr479His.
###end p 34
###begin p 35
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human embryonic kidney 293T cells were bought from the American Type Culture Collection (ATCC, Rockville, MD). Transient expression of wild-type and mutant myocilins was performed as described [25]. An expression analysis of the different myocilin forms was performed by western immunoblot using an anti-myc antibody (9E10, Santa Cruz, Valencia, CA) diluted at 1:400-1:500 [25]. Fluorescence microscopy was also carried out as described [25].
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
###xml 13 21 <span type="species:ncbi:9606">patients</span>
Phenotype of patients
###end title 37
###begin p 38
###xml 289 295 289 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 373 379 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 498 505 498 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 639 646 639 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 810 817 810 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 508 516 <span type="species:ncbi:9606">Patients</span>
###xml 748 756 <span type="species:ncbi:9606">patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
###xml 1035 1043 <span type="species:ncbi:9606">patients</span>
###xml 1132 1140 <span type="species:ncbi:9606">patients</span>
A total of 110 unrelated and sporadic POAG patients were studied. In addition, we analyzed 40 cases diagnosed with OHT. The control group included 98 individuals in whom glaucoma was ruled out. The main clinical features of most of these subjects have been reported in a previous study of CYP1B1 mutations in Spanish patients with POAG [17]. Subjects with mutations in the CYP1B1 gene were not included in the present study. The three groups were homogeneous with respect to gender and age (p>0.1; Table 4). Patients were under medical treatment to reduce IOP. Therefore, their IOP mean values were below 21 mmHg at the time of the study (Table 4), which indicated that treatment was effective. The mean IOP and C/D ratios in both eyes of glaucoma patients were significantly higher (p<0.01) than in controls (Table 4). The visual field status of the eyes from POAG patients was severe for 12.7%, moderate for 27.4%, early for 49.6%, and normal for 7.3%. The visual field could not be determined in 3.0% of eyes. Normal eyes were from patients who showed monolateral visual field alterations. The visual field was normal in the OHT patients.
###end p 38
###begin title 39
###xml 28 40 <span type="species:ncbi:9606">participants</span>
Clinical characteristics of participants in the study.
###end title 39
###begin p 40
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
Details of clinical features of 40 OHT, 110 POAG patients, and 98 unaffected controls are shown in the table. Since this is a retrospective study, IOP values before medical treatment were generally not available. C/D indicates cup-disc ratio of optic nerve; OD indicates right eye; OS indicates left eye; and SD indicates standard deviation. The three groups were homogeneous with respect to gender and age. Mean IOP and C/D ratios in glaucoma patients were higher than in controls. In the "Variable" column, the listed age was at the time of the study.
###end p 40
###begin title 41
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
Identification of myocilin sequence variations and genotype-phenotype correlation
###end title 41
###begin p 42
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 814 822 814 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 827 834 827 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 1047 1055 1047 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 1322 1330 1322 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 1590 1597 1590 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 1773 1780 1773 1780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 1843 1845 1843 1845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 1860 1862 1860 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 1951 1955 1951 1955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 2003 2010 2003 2010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 2015 2022 2015 2022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 2095 2103 2095 2103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 2173 2180 2173 2180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 2185 2192 2185 2192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
###xml 1559 1567 <span type="species:ncbi:9606">patients</span>
Genomic DNA from each of 110 POAG and 40 OHT unrelated Spanish patients was screened by direct PCR sequencing for mutations in the promoter (nucleotides -1 to -1117) and in the three exons including consensus splicing sequences of the MYOC gene. OHT patients were investigated because elevated IOP is one of the major risk factors for the development of glaucoma and in our group of POAG patients, OHT was the first stage of the disease. The same genetic analysis was performed in 98 control subjects. Allele and genotype frequencies for all sequence variations were calculated. Genotype frequencies did not deviate from the Hardy-Weinberg equilibrium (data not shown). We identified six common SNPs (MAF >5% in at least one group) in the promoter region: -1000C>G, -387C>T, -306G>A, -224T>C, -126T>C, and -83G>A (Figure 1 and Table 5). Two of them were located close to two consensus sequences: SNP -224T>C was mapped next to the 3' end of one negative glucocorticoid response element (nGRE) and SNP -83G>A was placed at the 3' end of a SAC box (Figure 1). The two consensus sequences are putatively involved in the regulation of myocilin expression. The promoter polymorphism, -387C>T, was located in a mammalian interspersed repeat (MIR) element [26]. We also detected a polymorphic GT microsatellite at position -339 (Figure 1) with seven alleles ranging from eleven to nineteen repetitions. Alleles 11, 16, and 19 presented the lowest frequencies in the three groups of subjects (0-1.6%) while allele 13 was the most frequent, ranging from 34.1% in POAG patients to 40.8% in controls (Table 5). Alleles 17 and 18 were not detected in our population. The genotype 13/15 was highly represented in the three groups and varied from 23.6% in POAG to 33.3% in OHT subjects (Table 6). This polymorphism has been previously described in Chinese [27] and Swedish [28] populations. We did not detect any statistically significant association between these MYOC promoter polymorphisms and either POAG or OHT (Table 5 and Table 6). We also observed the common coding SNP, Arg76Lys, in this population (Figure 1) with similar allele and genotype frequencies in cases and controls (Table 5 and Table 6).
###end p 42
###begin p 43
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
###xml 749 751 749 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 752 754 752 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r63">63</xref>
###xml 25 30 <span type="species:ncbi:9606">human</span>
Genomic structure of the human myocilin gene and location of identified DNA sequence variations. The promoter and the three exons are represented by boxes. Consensus regulatory sequences in the promoter region are depicted in the inset. Pathogenic mutations and polymorphisms in the coding region are indicated by solid and dashed arrows, respectively. Sequence variations in the promoter region are shown by arrowheads. Novel mutations are shown by asterisks. All mutations are defined in terms of the one-letter code. Designated features include AP-1-like and AP-2-like sequences, putative TATA and SAC boxes, glucocorticoid response element (GRE), negative glucocorticoid response element (nGRE), thyroid response element (TRE) and a MIR repeat [26,63]. -700_699ins: -700_699insCAGACACACATATACATGCACATACACA.
###end p 43
###begin title 44
###xml 22 30 22 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
Allele frequencies of myocilin promoter and coding sequence variations in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.
###end title 44
###begin p 45
The full description of -700_699ins is -700_699insCAGACACACATATACATGCACATACACA. In the table, I indicates the insertion allele, WT indicates the wild-type allele, and n is the total number of chromosomes. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.
###end p 45
###begin title 46
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
Genotype frequencies of myocilin promoter and coding sequence variations in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.
###end title 46
###begin p 47
The full description of -700_699ins is -700_699insCAGACACACATATACATGCACATACACA. In the table, I indicates the insertion allele, WT indicates the wild-type allele, and n is the total number of chromosomes. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.
###end p 47
###begin p 48
###xml 261 269 261 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 274 281 274 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 337 344 337 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 349 356 349 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 639 646 639 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 651 658 651 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 718 726 718 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 935 943 935 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 1006 1007 1006 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 1112 1119 1112 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 1124 1131 1124 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t6">Table 6</xref>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
In addition, nine sequence variations with MAFs greater than or equal to 5% were identified: -700_699ins, -315G>A, -190G>T, c.499A>G (Leu159Leu), c.520G>C (Leu166Leu), c.877G>T (Thr285Thr), c.997G>A (Thr325Thr), c.1063T>C (Tyr347Tyr), and c.1215A>G (Lys398Arg; Figure 1 and Table 5). The last SNP was detected only in a control subject (Table 5 and Table 6). To the best of our knowledge two of these SNPs (-315G>A and -190G>T) and the 28 bp insertion (-700_699insCAGACACACATATACATGCACATACACA) have not been previously described. They were found in two different OHT patients (-315G>A and -700_699ins) and in one control subject (-190G>T; Table 5 and Table 6). The 28 bp insertion was located in an AP1-like sequence (Figure 1). Of the remaining six rare polymorphisms, five were synonymous mutations (Leu159Leu, Leu166Leu, Thr285Thr, Thr325Thr, and Tyr347Tyr), while one (Lys398Arg) originated a conservative amino acid substitution (Figure 1). All of them except Leu166Leu have been previously reported [8,29]. Association analysis of these polymorphisms with the disease was limited by their low frequencies (Table 5 and Table 6).
###end p 48
###begin title 49
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Myocilin</italic>
Myocilin linkage disequilibrium structure
###end title 49
###begin p 50
###xml 62 66 62 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 197 205 197 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
To determine the linkage disequilibrium (LD) structure of the MYOC gene in our population, we evaluated in the control group pairwise LD between all SNPs with MAF >5%. Two LD blocks were detected (Figure 2). Block 1 comprises SNPs -1000C>G and -387C>T (D'=1.0; D' confidence bounds=0.88-1.0) while block 2 is composed of SNPs -83G>A and Arg76Lys (D'=0.95; D' confidence bounds=0.80-0.99). The same LD structure was observed in glaucoma patients (data not shown).
###end p 50
###begin p 51
###xml 43 51 43 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
###xml 142 146 142 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
Pairwise linkage disequilibrium pattern of myocilin single nucleotide polymorphisms measured by D'. The location of each tested SNP along the MYOC gene is indicated at the top. The strength of LD is depicted by grey intensity, which moves from light grey to black as D' progresses from 0 to 1.
###end p 51
###begin title 52
Haplotype analysis
###end title 52
###begin p 53
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 299 306 299 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t7">Table 7</xref>
###xml 524 531 524 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t7">Table 7</xref>
MYOC SNPs with MAF >5% were used to construct predicted haplotypes, taking into account only one SNP from each LD block (-1000C >G from block 1 and -83G>A from block 2). Twenty haplotypes with frequencies >2% were inferred from our data, but only five exhibited frequencies >5% in the three groups (Table 7). The rare inferred haplotypes (<5%) were pooled in one class to allow comparison between cases and controls. We did not find any significant differences in predicted haplotype frequencies between cases and controls (Table 7), which indicates that they do not contribute to the development of glaucoma.
###end p 53
###begin title 54
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
Frequencies of myocilin inferred haplotypes in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.
###end title 54
###begin p 55
Haplotypes were constructed with polymorphisms, -1000, -339(GT)11-19, -306, -224, -126 and -83. Predicted haplotypes with frequencies lower than 2% were not considered. Only haplotypes with frequencies higher than 5% in all groups are shown. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.
###end p 55
###begin title 56
###xml 18 26 18 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
Identification of myocilin pathogenic mutations in sporadic primary open-angle glaucoma cases
###end title 56
###begin p 57
###xml 126 134 126 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 139 146 139 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t8">Table 8</xref>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 587 594 587 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t8">Table 8</xref>
###xml 870 877 870 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t8">Table 8</xref>
###xml 1063 1070 1063 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t8">Table 8</xref>
###xml 1316 1323 1316 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t8">Table 8</xref>
###xml 1420 1424 1420 1424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 1890 1897 1890 1897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t8">Table 8</xref>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 637 644 <span type="species:ncbi:9606">patient</span>
###xml 913 920 <span type="species:ncbi:9606">patient</span>
###xml 947 954 <span type="species:ncbi:9606">patient</span>
###xml 1227 1234 <span type="species:ncbi:9606">patient</span>
###xml 1356 1363 <span type="species:ncbi:9606">patient</span>
###xml 1758 1765 <span type="species:ncbi:9606">patient</span>
One non-sense (Gln368stop) and two missense (Ala445Val and Tyr479His) mutations were identified in three POAG patients (2.7%; Figure 1 and Table 8). All of them were present in heterozygosis and affected amino acid positions located in the olfactomedin-like domain (exon 3) of myocilin. Two of these mutations (Gln368Stop and Ala445Val) were previously reported in POAG [8,30] and as far as we know, the third mutation (Tyr479His) has been detected for the first time in the present study. Ages at diagnosis ranged from 32 to 56 years in this group of POAG patients (mean of 51.6 years; Table 8). In our sample, the mutation Gln368Stop (patient number 67) was associated with a severe phenotype featured by severe visual field alteration, high optic disk excavation, and resistance to medical treatment, which requires filtration surgery for an adequate control of IOP (Table 8). Carriers of mutations Ala445Val (patient number 50) and Tyr479His (patient number 3) showed early alteration of the visual field and their IOPs were adequately controlled with drugs (Table 8). The Tyr479His mutation was associated with an early-onset of the disease (32 years). Additionally, we also found the novel myocilin mutation Arg346Thr in patient number 19 who was diagnosed with glaucoma at 44 years and showed a narrow-angle (Table 8). Due to the narrow-angle, this patient was not included in the group of POAG subjects carrying MYOC mutations. After diagnosis, this subject underwent Nd:YAG laser iridotomy to prevent acute angle-closure glaucoma followed by treatment with three drugs (pilocarpine, dorzolamide, and timolol) to reduce IOP. In spite of this treatment, he required filtration surgery for the correct control of IOP. After 22 years of evolution, this patient displayed an extreme clinical phenotype characterized by bilateral and severe visual field alteration and large C/D ratios (Table 8).
###end p 57
###begin title 58
###xml 55 63 55 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myocilin</italic>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
Clinical features of glaucoma patients with pathogenic myocilin mutations.
###end title 58
###begin p 59
###xml 38 42 38 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
Mutation information was based on the MYOC GenBank accession number: . IOP values were obtained following medical treatment. IOP records before treatment were not always available. The asterisk indicates novel mutations. IOP: intraocular pressure, OD: right eye, OS: left eye, C/D: cup-disc ratio of optic nerve, ND: not determined due to oblique insertion of the optic nerve head.
###end p 59
###begin title 60
Evaluation of the two novel myocilin mutations pathogenicity by multiple sequence alignment and transient expression in 293T cells
###end title 60
###begin p 61
###xml 717 725 717 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 502 507 <span type="species:ncbi:9606">human</span>
We used three approaches to evaluate the pathogenicity of the novel mutations: (a) analysis of evolutionary conservation of affected amino acids; (b) prediction of physicochemical changes induced by the different mutations; and (c) study of expression and subcellular distribution of cloned mutant and wild-type myocilin in transiently transfected 293T cells. Comparison of amino acid sequence alignment among myocilin from different species as well as with other members of the olfactomedin family of human proteins (olfactomedin-1 and optimedin) showed that the two novel mutations affected highly conserved amino acid residues (Arg346 and Tyr479), which are located in two regions of predicted beta-sheet folding (Figure 3). In addition, the two novel non-conservative mutations altered the predicted physicochemical properties of the polypeptide chain. The positive charge of Arg at position 346 is substituted by the polar Thr side chain in the mutant protein. Similarly, the hydrophobic Tyr is replaced by the polar His residue at amino acid position 479. These predicted amino acid changes could disrupt the secondary structure of myocilin, resulting in protein misfolding.
###end p 61
###begin p 62
Multiple amino acid sequence alignment of myocilin from different species. Sequence alignment was generated by . Residues affected by mutations are indicated by arrowheads. Asterisks indicate amino acid positions at which all query sequences are identical. Amino acid positions at which all analyzed sequences have amino acids that are chemically similar are denoted by two dots (:). One dot denotes amino acid positions with weak chemical similarity (.). Arrows indicated regions of the polypeptide chain which are predicted to fold into a beta-sheet conformation.
###end p 62
###begin p 63
###xml 167 175 167 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 465 473 465 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 664 672 664 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4</xref>
###xml 808 810 808 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
Transient expression of the two novel missense myocilin mutants in 293T cells showed that they accumulated intracellularly, mainly in the insoluble cellular fraction (Figure 4). The same behavior was observed with the myocilin mutation, Pro370Leu, which was used as a control because it is associated with one of the most severe myocilin glaucoma phenotypes [31]. A 35 kDa myocilin fragment was present in the culture medium of cells expressing wild-type myocilin (Figure 4, culture medium lanes), which is produced by proteolytic cleavage of the protein [25]. This fragment was neither detected in the two myocilin mutants nor in the control mutation, Pro370Leu (Figure 4), indicating that the proteolytic processing is reduced by these mutations, as previously described for myocilin pathogenic mutations [25].
###end p 63
###begin p 64
Western immunoblot of two novel myocilin mutations found in this study and expressed in transiently transfected 293T cells. Two hundred nanograms of DNA constructs encoding myc epitope-tagged versions of mutant myocilin forms (Arg346Thr, Tyr479His, Gln368Stop and Pro370Leu) were transfected into 293T cells. Separation of culture medium, soluble cellular fractions, and insoluble cellular fractions were carried out as indicated in the Materials and Methods. Detection was performed with an anti-myc monoclonal antibody. Myc-tagged wild-type myocilin was used as a control of normal expression and the myocilin mutation Pro370Leu was employed as a control of disease-causing mutation. The arrow and arrowhead indicate the position of the 55 kDa and 35 kDa myocilin bands, respectively. c.m.: culture medium; s.c.f.: soluble cellular fraction; i.c.f.: insoluble cellular fraction.
###end p 64
###begin p 65
###xml 150 159 150 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5B</xref>
###xml 164 173 164 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5C</xref>
###xml 514 523 514 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5A</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
Immunocytochemical analysis of the two novel mutant myocilins transiently expressed in 293T cells revealed intense granular signals in the cytoplasm (Figure 5B and Figure 5C). This indicates most of the mutant myocilins accumulated intracellularly in the ER as misfolded proteins. This staining pattern clearly contrasted with that of wild-type myocilin, which was distributed in a reticular network located around the nucleus and cytoplasm and labeled a perinuclear structure compatible with the Golgi apparatus (Figure 5A). These results agree with previous reports [25,32-36] and strongly support that the two novel mutations found in the glaucoma patients are pathogenic.
###end p 65
###begin p 66
###xml 218 219 218 219 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 256 257 256 257 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 274 275 274 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 334 335 334 335 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 66 71 <span type="species:ncbi:9606">human</span>
Subcellular distribution in transiently transfected 293T cells of human wild-type myocilin-GFP and two novel myocilin mutations found in this study. Two hundred nanograms of DNA constructs encoding wild-type myocilin (A), mutant myocilin forms, Arg346Thr (B) and Tyr479His (C), and the control, Pro370Leu (a disease causing mutation; D) were transfected into 293T cells. Wild-type myocilin was mainly detected in structures compatible with the Golgi apparatus and secretory vesicles. Note that the three mutant versions accumulated in the ER. The asterisk indicates the location of the Golgi apparatus. Arrows indicate the position of intracellular myocilin aggregates. Original magnification: X1600.
###end p 66
###begin title 67
###xml 12 22 12 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">optineurin</italic>
Analysis of optineurin sequence variations in sporadic cases of primary open-angle glaucoma
###end title 67
###begin p 68
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 334 341 334 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t9">Table 9</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 597 604 597 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t9">Table 9</xref>
###xml 711 719 711 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t10">Table 10</xref>
###xml 842 849 842 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t8">Table 8</xref>
###xml 854 861 854 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t9">Table 9</xref>
###xml 889 893 889 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
To evaluate the role of OPTN DNA sequence variations in Spanish patients affected by POAG, we screened the complete coding region of the gene in cases and controls by SSCP. Analysis by PCR DNA sequencing of the SSCP positive samples revealed two different G>A transitions, which originated two synonymous SNPs: Thr34Thr and Leu41Leu (Table 9). Both SNPs mapped to exon 4 and have been previously described in other populations [18,37-40]. Thr34Thr is a common polymorphism in our population, whereas Leu41Leu is a relatively rare one with MAFs of 1.8% and 2.6% in POAG and controls, respectively (Table 9). The low frequency allele (A) was not detected in the OHT group. Their genotype frequencies are shown in Table 10. There were no statistically significant differences in either allele or genotype frequencies between cases and controls (Table 8 and Table 9). These data indicate that OPTN DNA sequence variations are not involved in high-pressure POAG in the Spanish population.
###end p 68
###begin title 69
###xml 22 32 22 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">optineurin</italic>
Allele frequencies of optineurin single nucleotide polymorphisms in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.
###end title 69
###begin p 70
###xml 5 6 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
A chi2 test or Fisher's exact test was used to compare allele frequencies in POAG or OHT patients with control subjects. Allele frequencies do not statistically differ between cases and controls. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.
###end p 70
###begin title 71
###xml 24 34 24 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">optineurin</italic>
Genotype frequencies of optineurin single nucleotide polymorphisms in primary open-angle glaucoma, adult-onset ocular hypertension, and control subjects.
###end title 71
###begin p 72
###xml 5 6 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
A chi2 test or Fisher's exact test was used to compare genotype frequencies in POAG or OHT patients with control subjects. Genotype frequencies do not statistically differ between cases and controls. The asterisk indicates POAG versus controls and the sharp (hash mark) indicates OHT versus controls.
###end p 72
###begin title 73
Discussion
###end title 73
###begin p 74
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 257 261 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
Information regarding the role of MYOC and OPTN in Spanish POAG patients is scarce. So, the contribution of OPTN sequence variations to POAG in Spain has not been analyzed so far. Therefore, the main purpose of this study was to analyze the contribution of MYOC and OPTN sequence variations to adult-onset glaucoma in patients from this country.
###end p 74
###begin p 75
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 702 703 702 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 842 846 842 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 986 987 986 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 988 989 988 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 993 995 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 996 998 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 348 355 <span type="species:ncbi:9606">patient</span>
###xml 976 984 <span type="species:ncbi:9606">patients</span>
###xml 1113 1120 <span type="species:ncbi:9606">patient</span>
We have found that heterozygous glaucoma MYOC mutations are located in the olfactomedin-like domain in 2.7% of POAG patients from Southeast Spain in accordance with frequencies reported in other populations [9,29]. One of the most interesting findings of this study was the identification of the novel mutation Tyr479His in an early-onset glaucoma patient with a mild phenotype. The high evolutionary conservation of the affected amino acid residue together with the biochemical and microscopy analysis supports the pathogenicity of this mutation. Two of the identified mutations, Gln368Stop and Ala445Val, have been previously described. Gln368Stop is the most common myocilin mutation found in POAG [8,29]. Interestingly, it is generally associated with late glaucoma onset (mean age at diagnosis 54.9 years) and low IOPs compared to other MYOC mutations [41]. Carriers of this mutation also show adequate responses to medical treatment similar to ordinary adult-onset POAG patients [8,9,29,30,41,42]. In contrast, our study found that Gln368Stop was associated with severe optic disk and visual damage and the patient who carried the mutation required surgery for a correct control of IOP. Since diagnosis was performed timely (at 56 years) further work is necessary to determine whether the phenotype is directly caused by this mutation or if it is influenced by other genetic and/or environmental factors.
###end p 75
###begin p 76
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 954 956 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 289 296 <span type="species:ncbi:9606">patient</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 809 816 <span type="species:ncbi:9606">patient</span>
###xml 944 952 <span type="species:ncbi:9606">patients</span>
###xml 1068 1075 <span type="species:ncbi:9606">patient</span>
Mutation Ala445Val has been previously found in OHT [43] and POAG patients from different populations [8,44]. The case subject who harboured this predicted amino acid substitution (number 50) showed a mild glaucoma phenotype. Noteworthy, a second novel mutation, Arg346Thr, was found in a patient with a narrow-angle. For this reason, it was not considered as a mutation found in POAG patients. Interestingly, this subject was diagnosed with glaucoma at 44 years of age, in contrast with typical closure-angle glaucoma which usually manifests at older ages. Preventive iridotomy to prevent pupillary block, followed by medical treatment with three drugs were not sufficient to reduce IOP thus required filtration surgery. These data indicate that the narrow angle is not the primary cause of glaucoma in this patient. Furthermore, it has been reported that myocilin mutations are not associated with angle-closure glaucoma, at least in Chinese patients [45]. Altogether, these data suggest that the narrow angle and the myocilin mutation could be coincidental in this patient and that Tyr479His could be involved in POAG development. Further investigations are required to determine the exact role of this mutation in POAG.
###end p 76
###begin p 77
###xml 36 40 36 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 556 560 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 632 640 <span type="species:ncbi:9606">patients</span>
A previous study identified 7.5% of MYOC mutation carriers in patients from Galicia (N. Spain), but only sequence variations in exon 3 were analyzed [46]. Apart from Gln368Stop, which has also been identified by Vazquez and co-workers, the spectrum of pathogenic mutations was different from that found in the present study. It remains to be investigated whether these differences can be attributed to different genetic backgrounds between these two Spanish subpopulations or to the sample size used in the two studies. The same researchers later analyzed MYOC mutations in exons 1 and 2 and in the promoter region of this group of patients. No mutations in these two exons were found, and although five sequence variations were identified in the promoter region, no association with the disease was established [47], which agrees with our results.
###end p 77
###begin p 78
###xml 100 106 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP1B1</italic>
###xml 68 76 <span type="species:ncbi:9606">patients</span>
###xml 290 298 <span type="species:ncbi:9606">patients</span>
In a previous study we found that approximately 10% of Spanish POAG patients carry mutations in the CYP1B1 gene [17], which is three times higher than the frequency of carriers of mutations in the MYOC gene. This data clearly shows the existence of genetic heterogeneity among Spanish POAG patients and indicates that CYP1B1 sequence alterations are the most important genetically known cause of POAG, at least in our population.
###end p 78
###begin p 79
###xml 43 47 43 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 600 604 600 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 817 819 817 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
In the present study we have identified 15 MYOC SNPs, one polymorphic GT microsatellite, and one 28 bp insertion. All these DNA sequence variations were distributed along the promoter and coding region of the gene. To the best of our knowledge, three of these SNPs (-315G>A, -190G>T, and Leu166Leu) and the -700_699ins have been identified here for the first time. None of the polymorphic DNA sequence variations showed significant association with glaucoma. Albeit some of these promoter SNPs were located in putative regulatory promoter sequences, it remains to be demonstrated whether they affect MYOC expression. In any event, it is unlikely that changes in the gene expression may contribute to myocilin glaucoma since development of the disease appears to be related with structural alterations of the protein [34,48,49].
###end p 79
###begin p 80
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 425 433 <span type="species:ncbi:9606">patients</span>
In accordance with previous reports, we found that allele and genotype frequencies of SNP -1000C>G were not significantly different in cases and controls [50-52]. Since Colomb et al reported the association of this SNP with the severity of POAG, there has been some controversy about the actual relationship with the disease. Our data support that there is no association between this polymorphism and the disease in Spanish patients.
###end p 80
###begin p 81
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r58">58</xref>
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
We detected two LD blocks composed of SNPs -1000C>G and -387C>T (block 1) and -83G>A and Arg76Lys (block 2). LD block 1 has been described in the Chinese population [53] whereas LD block 2 has been found in Asian [53-58] and European populations [10]. Analysis of inferred six loci haplotypes further confirmed no association of MYOC promoter polymorphisms with either OHT or POAG in the studied Spanish population.
###end p 81
###begin p 82
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r59">59</xref>
###xml 163 165 163 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r61">61</xref>
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r62">62</xref>
Defects in OPTN have been clearly implicated in normal tension glaucoma (NTG) [18,40], but its role in high-pressure glaucoma has been a source of controversy [59-61]. In accordance with previous reports, our data indicate that OPTN does not contribute to the development of either OHT or typical adult-onset high-pressure glaucoma, at least in the Spanish population [62].
###end p 82
###begin p 83
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 65 69 65 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">OPTN</italic>
The present study provides new insight into the role of MYOC and OPTN genes in POAG in Spain and brings new information to unravel genetic alterations associated with POAG in this country.
###end p 83
###begin title 84
Acknowledgements
###end title 84
###begin p 85
###xml 145 151 <span type="species:ncbi:490835">Fresno</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
We thank Dr. Juan Lopez-Moya, Chairman of the "Servicio de Oftalmologia, Complejo Hospitalario Universitario de Albacete" and Dr. Ricardo Fraile-Fresno for supporting this project. We also thank Mrs. Ana Maria Alonso and Mrs. Carmen Cifuentes for technical assistance and the nurses of the "Servicio de Oftalmologia" for extracting blood samples. We are also indebted to Mr. Jose Daniel Aroca-Aguilar for his invaluable collaboration in DNA sequencing. We wish to cordially thank patients and control subjects for their cooperation in the study. Supported in part by research grants PI052494, 02021- 00, and PAI-02-049 from the "Fondo de Investigaciones Sanitarias", "Consejeria de Sanidad", and "Consejeria de Ciencia y Tecnologia de la Junta de Comunidades de Castilla-La Mancha", respectively (to J.E.); and from NIH grant EY04873 and a Research to Prevent Blindness Lew Waserman Merit Award (to M.C-P.). Maria-Pilar Lopez-Garrido was a recipient of a fellowship from the "Consejeria de Sanidad de la Junta de Comunidades de Castilla-La Mancha". The authors have no financial or proprietary conflicts relevant to the content of this paper.
###end p 85
###begin title 86
References
###end title 86
###begin article-title 87
Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis.
###end article-title 87
###begin article-title 88
An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage.
###end article-title 88
###begin article-title 89
Untreated ocular hypertension. A long-term prospective study.
###end article-title 89
###begin article-title 90
Neuronal death in glaucoma.
###end article-title 90
###begin article-title 91
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Increased DNA breaks and up-regulation of both G(1) and G(2) checkpoint genes p21(WAF1/CIP1) and 14-3-3 sigma in circulating leukocytes of glaucoma patients and vasospastic individuals.
###end article-title 91
###begin article-title 92
Prevalence of myocilin mutations in adults with primary open-angle glaucoma in Ghana, West Africa.
###end article-title 92
###begin article-title 93
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma.
###end article-title 93
###begin article-title 94
Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A).
###end article-title 94
###begin article-title 95
Identification of a gene that causes primary open angle glaucoma.
###end article-title 95
###begin article-title 96
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Myocilin analysis by DHPLC in French POAG patients: increased prevalence of Q368X mutation.
###end article-title 96
###begin article-title 97
###xml 133 138 <span type="species:ncbi:9606">human</span>
Isolation and characterization of cell-specific cDNA clones from a subtractive library of the ocular ciliary body of a single normal human donor: transcription and synthesis of plasma proteins.
###end article-title 97
###begin article-title 98
###xml 56 61 <span type="species:ncbi:9606">human</span>
Cloning and characterization of subtracted cDNAs from a human ciliary body library encoding TIGR, a protein involved in juvenile open angle glaucoma with homology to myosin and olfactomedin.
###end article-title 98
###begin article-title 99
###xml 86 91 <span type="species:ncbi:9606">human</span>
Expression of the TIGR gene in the iris, ciliary body, and trabecular meshwork of the human eye.
###end article-title 99
###begin article-title 100
###xml 27 35 <span type="species:ncbi:9606">patients</span>
CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma.
###end article-title 100
###begin article-title 101
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Association of a common coding polymorphism (N453S) of the cytochrome P450 1B1 (CYP1B1) gene with optic disc cupping and visual field alteration in French patients with primary open-angle glaucoma.
###end article-title 101
###begin article-title 102
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Primary role of CYP1B1 in Indian juvenile-onset POAG patients.
###end article-title 102
###begin article-title 103
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Heterozygous CYP1B1 gene mutations in Spanish patients with primary open-angle glaucoma.
###end article-title 103
###begin article-title 104
Adult-onset primary open-angle glaucoma caused by mutations in optineurin.
###end article-title 104
###begin article-title 105
Staining nucleic acids with silver: an alternative to radioisotopic and fluorescnece labeling.
###end article-title 105
###begin article-title 106
On measures of gametic disequilibrium.
###end article-title 106
###begin article-title 107
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 107
###begin article-title 108
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome.
###end article-title 108
###begin article-title 109
PowerMarker: an integrated analysis environment for genetic marker analysis.
###end article-title 109
###begin article-title 110
Myocilin mutations causing glaucoma inhibit the intracellular endoproteolytic cleavage of myocilin between amino acids Arg226 and Ile227.
###end article-title 110
###begin article-title 111
Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells.
###end article-title 111
###begin article-title 112
TIGR/MYOC proximal promoter GT-repeat polymorphism is not associated with myopia.
###end article-title 112
###begin article-title 113
No evidence of association between GT/CA-repeat polymorphism in the GLC1A gene promoter and primary open-angle or exfoliation glaucoma.
###end article-title 113
###begin article-title 114
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Analysis of myocilin mutations in 1703 glaucoma patients from five different populations.
###end article-title 114
###begin article-title 115
Myocilin Gln368stop mutation and advanced age as risk factors for late-onset primary open-angle glaucoma.
###end article-title 115
###begin article-title 116
Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma.
###end article-title 116
###begin article-title 117
Altered secretion of a TIGR/MYOC mutant lacking the olfactomedin domain.
###end article-title 117
###begin article-title 118
Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma.
###end article-title 118
###begin article-title 119
Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor.
###end article-title 119
###begin article-title 120
Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma.
###end article-title 120
###begin article-title 121
Expression of wild-type and truncated myocilins in trabecular meshwork cells: their subcellular localizations and cytotoxicities.
###end article-title 121
###begin article-title 122
###xml 107 115 <span type="species:ncbi:9606">patients</span>
SNPs and interaction analyses of myocilin, optineurin, and apolipoprotein E in primary open angle glaucoma patients.
###end article-title 122
###begin article-title 123
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Variants in optineurin gene and their association with tumor necrosis factor-alpha polymorphisms in Japanese patients with glaucoma.
###end article-title 123
###begin article-title 124
###xml 22 30 <span type="species:ncbi:9606">patients</span>
OPTN gene: profile of patients with glaucoma from India.
###end article-title 124
###begin article-title 125
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Evaluation of optineurin sequence variations in 1,048 patients with open-angle glaucoma.
###end article-title 125
###begin article-title 126
###xml 94 102 <span type="species:ncbi:9606">patients</span>
A case-control comparison of the clinical characteristics of glaucoma and ocular hypertensive patients with and without the myocilin Gln368Stop mutation.
###end article-title 126
###begin article-title 127
Gln368STOP myocilin mutation in families with late-onset primary open-angle glaucoma.
###end article-title 127
###begin article-title 128
Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene.
###end article-title 128
###begin article-title 129
Founder TIGR/myocilin mutations for glaucoma in the Quebec population.
###end article-title 129
###begin article-title 130
Molecular analysis of the myocilin gene in Chinese subjects with chronic primary-angle closure glaucoma.
###end article-title 130
###begin article-title 131
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Mutations in the third exon of the MYOC gene in spanish patients with primary open angle glaucoma.
###end article-title 131
###begin article-title 132
Mutations including the promoter region of myocilin/TIGR gene.
###end article-title 132
###begin article-title 133
Anterior segment development relevant to glaucoma.
###end article-title 133
###begin article-title 134
Mutant myocilin nonsecretion in vivo is not sufficient to cause glaucoma.
###end article-title 134
###begin article-title 135
###xml 35 43 <span type="species:ncbi:9606">patients</span>
Variations in the myocilin gene in patients with open-angle glaucoma.
###end article-title 135
###begin article-title 136
Association of a single nucleotide polymorphism in the TIGR/MYOCILIN gene promoter with the severity of primary open-angle glaucoma.
###end article-title 136
###begin article-title 137
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Myocilin mt1 promoter polymorphism in Turkish patients with primary open angle glaucoma.
###end article-title 137
###begin article-title 138
Polymorphisms in the myocilin promoter unrelated to the risk and severity of primary open-angle glaucoma.
###end article-title 138
###begin article-title 139
Truncations in the TIGR gene in individuals with and without primary open-angle glaucoma.
###end article-title 139
###begin article-title 140
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Analysis of myocilin gene mutations in Japanese patients with normal tension glaucoma and primary open-angle glaucoma.
###end article-title 140
###begin article-title 141
Absence of myocilin and optineurin mutations in a large Philippine family with juvenile onset primary open angle glaucoma.
###end article-title 141
###begin article-title 142
TIGR/MYOC gene sequence alterations in individuals with and without primary open-angle glaucoma.
###end article-title 142
###begin article-title 143
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Mutations in MYOC gene of Indian primary open angle glaucoma patients.
###end article-title 143
###begin article-title 144
Different optineurin mutation pattern in primary open-angle glaucoma.
###end article-title 144
###begin article-title 145
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Lack of association of mutations in optineurin with disease in patients with adult-onset primary open-angle glaucoma.
###end article-title 145
###begin article-title 146
###xml 88 96 <span type="species:ncbi:9606">patients</span>
The M98K variant of the OPTINEURIN (OPTN) gene modifies initial intraocular pressure in patients with primary open angle glaucoma.
###end article-title 146
###begin article-title 147
Optineurin gene is not involved in the common high-tension form of primary open-angle glaucoma.
###end article-title 147
###begin article-title 148
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human myocilin/TIGR gene transcription in trabecular meshwork cells and astrocytes: role of upstream stimulatory factor.
###end article-title 148

